The Biogen Thesis: "Stocks sometime run counter to expectations, as negative changes in business fundamentals can clear the way for significant upside catalysts," Harrison said in a Monday upgrade note.Biogen has downside risk in the near-term due to generic launches for its multiple sclerosis drug Tecfidera, which contributes around 30% of the company’s total product sales, the analyst said.